Morphic Holding, Inc.

NasdaqGM:MORF Stock Report

Market Cap: US$2.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Morphic Holding Past Earnings Performance

Past criteria checks 0/6

Morphic Holding's earnings have been declining at an average annual rate of -30.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 3% per year.

Key information

-30.27%

Earnings growth rate

18.81%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-3.04%
Return on equity-29.08%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Analysis Article • Jun 26

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 20

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Sep 29

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 07

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 15

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Market forces rained on the parade of Morphic Holding, Inc. ( NASDAQ:MORF ) shareholders today, when the analysts...
Analysis Article • Jan 03

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 08

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Today is shaping up negative for Morphic Holding, Inc. ( NASDAQ:MORF ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 03

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Morphic press release (NASDAQ:MORF): Q2 GAAP EPS of -$0.68 beats by $0.17. Revenue of $60.2M (+1463.6% Y/Y). As of June 30, 2022, Morphic had cash, cash equivalents and marketable securities of $397.6 million, compared to $380.7 million as of March 31, 2022.  Shares +3.95% PM.
Analysis Article • May 06

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

Today is shaping up negative for Morphic Holding, Inc. ( NASDAQ:MORF ) shareholders, with the analysts delivering a...
Analysis Article • Mar 01

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

The analysts covering Morphic Holding, Inc. ( NASDAQ:MORF ) delivered a dose of negativity to shareholders today, by...
Analysis Article • Feb 17

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 03

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Morphic Holding...
Seeking Alpha • Oct 13

Morphic: Pioneering Integrin Medicines

Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a unique technology platform to design selective oral therapies for integrins. Morphic recently reported promising phase 1 data for its lead asset, MORF-057 establishing safety. Now the company is bringing their lead asset into phase 2 trials; however, with the concentration risk and current valuation, Morphic is a stock worth monitoring as the trial progresses.

Revenue & Expenses Breakdown

How Morphic Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:MORF Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-180470
31 Mar 240-161410
31 Dec 231-152390
30 Sep 237-136370
30 Jun 239-130350
31 Mar 2369-64340
31 Dec 2271-59320
30 Sep 2274-56320
30 Jun 2275-51310
31 Mar 2219-106290
31 Dec 2120-96280
30 Sep 2116-92250
30 Jun 2139-61230
31 Mar 2143-50200
31 Dec 2045-45180
30 Sep 2039-47170
30 Jun 2019-61150
31 Mar 2017-55130
31 Dec 1917-43100
30 Sep 1921-2990
30 Jun 1915-2770
31 Mar 199-2460
31 Dec 183-2450

Quality Earnings: MORF is currently unprofitable.

Growing Profit Margin: MORF is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MORF is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.

Accelerating Growth: Unable to compare MORF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MORF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).

Return on Equity

High ROE: MORF has a negative Return on Equity (-29.08%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/15 00:07
End of Day Share Price 2024/08/15 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Morphic Holding, Inc. is covered by 9 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Guyn KimBMO Capital Markets Equity Research
Julian HarrisonBTIG